A MULTICENTER, DOUBLE-MASKED, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF RV 001, AN INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-1R) ANTAGONIST ANTIBODY (FULLY HUMAN), ADMINISTERED EVERY 3 WEEKS (Q3W) BY INTRAVENOUS (IV) INFUSION IN PATIENTS SUFFE